RUSSO, Domenico
 Distribuzione geografica
Continente #
NA - Nord America 365
AS - Asia 82
EU - Europa 51
SA - Sud America 12
AF - Africa 9
Totale 519
Nazione #
US - Stati Uniti d'America 359
SG - Singapore 40
CN - Cina 27
IE - Irlanda 20
BR - Brasile 12
IT - Italia 10
BE - Belgio 9
SN - Senegal 6
VN - Vietnam 6
CA - Canada 4
IN - India 4
UA - Ucraina 3
CI - Costa d'Avorio 2
DE - Germania 2
RU - Federazione Russa 2
AE - Emirati Arabi Uniti 1
AT - Austria 1
CH - Svizzera 1
FR - Francia 1
GB - Regno Unito 1
HN - Honduras 1
JM - Giamaica 1
KE - Kenya 1
LB - Libano 1
LT - Lituania 1
OM - Oman 1
TR - Turchia 1
UZ - Uzbekistan 1
Totale 519
Città #
Houston 174
Santa Clara 44
Singapore 27
Chandler 26
Dublin 20
Chicago 16
Brussels 9
Boardman 8
Andover 6
Beijing 6
Cambridge 6
Civitanova Marche 6
Dakar 6
Falls Church 6
Lawrence 6
Ashburn 4
Columbus 4
Des Moines 4
Dong Ket 4
The Dalles 4
Wilmington 4
Nanjing 3
Shenyang 3
Zhengzhou 3
Abidjan 2
Brooklyn 2
Frankfurt Am Main 2
Hanoi 2
Kochi 2
Los Angeles 2
Ottawa 2
Redwood City 2
Toronto 2
Alfenas 1
Ann Arbor 1
Cabo Frio 1
Chennai 1
Coelho Neto 1
Dallas 1
Dubai 1
El Progreso 1
Eusébio 1
Fazenda Nova 1
Franco da Rocha 1
Giresun 1
Hebei 1
Jacksonville 1
Jandira 1
Jiaxing 1
Kunming 1
Laranjal Paulista 1
London 1
Mandeville 1
Miami 1
Muscat 1
New York 1
Norwalk 1
Oak Park 1
Osasco 1
Portmore 1
Porto Alegre 1
Presidente Dutra 1
Providence 1
Richmond 1
Saint Petersburg 1
San Jose 1
Seattle 1
Tianjin 1
Torre A Mare 1
Washington 1
Yingkou 1
Totale 455
Nome #
Baseline factors associated with response to ruxolitinib: An independent study on 408 patients with myelofibrosis 170
Impact of comorbidities and body mass index in patients with myelofibrosis treated with ruxolitinib 122
Managing chronic myeloid leukemia for treatment-free remission: a proposal from the GIMEMA CML WP 71
Epidemiology, outcome, and risk factors for infectious complications in myelofibrosis patients receiving ruxolitinib: A multicenter study on 446 patients 67
Differences in presenting features, outcome and prognostic models in patients with primary myelofibrosis and post-polycythemia vera and/or post-essential thrombocythemia myelofibrosis treated with ruxolitinib. New perspective of the MYSEC-PM in a large multicenter study 51
Second primary malignancy in myelofibrosis patients treated with ruxolitinib 51
Totale 532
Categoria #
all - tutte 1.702
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 1.702


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202114 0 0 0 2 5 1 0 0 1 0 1 4
2021/202248 3 8 0 0 8 6 8 1 3 0 1 10
2022/202376 6 1 4 4 7 16 1 17 15 0 5 0
2023/202434 1 14 1 0 3 2 1 2 0 0 7 3
2024/2025147 1 25 9 14 35 22 1 4 8 13 12 3
2025/202619 16 3 0 0 0 0 0 0 0 0 0 0
Totale 532